This study was designed to evaluate the efficacy of infliximab in patients with Crohn's disease of durations less than one year.Methods:
Two nationwide surveys of 35 Japanese institutions majoring in inflammatory bowel disease identified 41 patients with active Crohn's disease who were treated by infliximab within 12 months after the diagnosis (E-group) and 97 patients treated later during their clinical course (L-group). Clinical features, responses to infliximab, and accompanying medications were compared between the two groups. A decrease in Crohn's disease activity index ≥70 or the index <150 two weeks after infliximab was regarded to be efficacious.Results:
The age was younger (24vs.33 years, median,P< 0.0001) and intestinal stricture (12vs.49 percent,P< 0.0001), internal fistula (0vs.26 percent,P= 0.0003), and previous intestinal resection (7vs.57 percent,P< 0.0001) were less frequent in the E-group than in the L-group. The efficacy of infliximab was different between the two groups with a significantly higher value in the E-group than in the L-group (90vs.61 percent,P= 0.0012). A multivariate logistic regression analysis revealed nonstricturing intestinal lesion to be a significant factor related to the efficacy of infliximab.Conclusion:
Infliximab is more efficacious in Crohn's disease with short duration, probably because of less frequent stenosis.